Heparan sulfate Ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 2, 2010, Pages 287-293

  Adhikari, Neeta ^a   Basi, David L ^b   Townsend, DeWayne ^a   Rusch, Melissa ^a,b   Mariash, Ami ^a   Mullegama, Sureni ^a   Watson, Adrienne ^a,b   Larson, Jon ^a   Tan, Sara ^a   Lerman, Ben ^a   Esko, Jeffrey D ^c,d   Selleck, Scott B ^a,b   Hall, Jennifer L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Development; Heparan sulfate; Ndst1; Proteoglycan; Remodeling; Vascular smooth muscle

Indexed keywords

HEPARAN SULFATE; N DEACETYLASE N SULFOTRANSFERASE 1; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED STUDY; FEMORAL ARTERY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SULFATION; VASCULAR SMOOTH MUSCLE;

AGING; ANIMALS; ANIMALS, NEWBORN; BLOOD VESSELS; CELL PROLIFERATION; FEMORAL ARTERY; GENE DELETION; HEART FUNCTION TESTS; HEPARITIN SULFATE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; ORGAN SIZE; SULFOTRANSFERASES; TUNICA INTIMA; TUNICA MEDIA;

MUS;

EID: 77953717811     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.02.022     Document Type: Article

References (41)

1. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71:435-471.
2. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68:729-777.
3. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
4. Fan G., Xiao L., Cheng L., Wang X., Sun B., Hu G. Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett. 2000, 467:7-11.
5. Ringvall M., Ledin J., Holmborn K., van Kuppevelt T., Ellin F., Eriksson I., Olofsson A.M., Kjellen L., Forsberg E. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J. Biol. Chem. 2000, 275:25926-25930.
6. Forsberg E., Kjellen L. Heparan sulfate: lessons from knockout mice. J. Clin. Invest. 2001, 108:175-180.
7. Francis D.J., Parish C.R., McGarry M., Santiago F.S., Lowe H.C., Brown K.J., Bingley J.A., Hayward I.P., Cowden W.B., Campbell J.H., Campbell G.R., Chesterman C.N., Khachigian L.M. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ. Res. 2003, 92:e70-e77.
8. Grobe K., Inatani M., Pallerla S.R., Castagnola J., Yamaguchi Y., Esko J.D. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 2005, 132:3777-3786.
9. Kinnunen T., Huang Z., Townsend J., Gatdula M.M., Brown J.R., Esko J.D., Turnbull J.E. Heparan 2-O-sulfotransferase, hst-2, is essential for normal cell migration in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1507-1512.
10. Pan Y., Woodbury A., Esko J.D., Grobe K., Zhang X. Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development 2006, 133:4933-4944.
11. Pallerla S.R., Pan Y., Zhang X., Esko J.D., Grobe K. Heparan sulfate Ndst1 gene function variably regulates multiple signaling pathways during mouse development. Dev. Dyn. 2007, 236:556-563.
12. Adhikari N., Rusch M., Mariash A., Li Q., Selleck S.B., Hall J.L. Alterations in heparan sulfate in the vessel in response to vascular injury in the mouse. J. Cardiovasc. Trans. Res. 2008, 1(3):236-240.
13. Kirkpatrick C.A., Selleck S.B. Heparan sulfate proteoglycans at a glance. J. Cell Sci. 2007, 120:1829-1832.
14. Frutkin A.D., Shi H., Otsuka G., Levéen P., Karlsson S., Dichek D.A. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J. Mol. Cell Cardiol. 2006, 41:724-731.
15. Xin H.B., Deng K.Y., Rishniw M., Ji G., Kotlikoff M.I. Smooth muscle expression of Cre recombinase and eGFP in transgenic mice. Physiol. Genomics 2002, 10:211-215.
16. Lepore J.J., Cheng L., Min Lu M., Mericko P.A., Morrisey E.E., Parmacek M.S. High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis 2005, 41:179-184.
17. Toyoda H., Kinoshita-Toyoda A., Fox B., Selleck S.B. Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu. Drosophila homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. J. Biol. Chem. 2000, 275:21856-21861.
18. Lawrence R., Lu H., Rosenberg R.D., Esko J.D., Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat. Methods 2008, 5:291-292.
19. Basi D.L., Adhikari N., Mariash A., Li Q., Kao E., Mullegama S.V., Hall J.L. Femoral artery neointimal hyperplasia is reduced after wire injury in Ref-1+/- mice. Am. J. Physiol. 2007, 292:H516-H521.
20. Wang X., Li Q., Adhikari N., Hall J.L. A role for muscle LIM protein (MLP) in vascular remodeling. J. Mol. Cell Cardiol. 2006, 40:503-509.
21. Sata M., Maejima Y., Adachi F., Fukino K., Saiura A., Sugiura S., Aoyagi T., Imai Y., Kurihara H., Kimura K., Omata M., Makuuchi M., Hirata Y., Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell Cardiol. 2000, 32:2097-2104.
22. David G., Bai X.M., Van der Schueren B., Cassiman J.J., Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J. Cell Biol. 1992, 119:961-975.
23. Wang X., Xiao Y., Mou Y., Zhao Y., Blankesteijn W.M., Hall J.L. A role for the {beta}-catenin/T-cell factor signaling cascade in vascular remodeling. Circ. Res. 2002, 90:340-347.
24. Prokunina-Olsson L., Welch C., Hansson O., et al. Tissue-specific alternative splicing of TCF7L2. Hum. Mol. Genet. 2009, 18:3795-3804.
25. Ray J.L., Leach R., Herbert J.M., Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001, 23:185-188.
26. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
27. Williams K.J., Liu M., Zhu Y., Davidson W.R., McCue P., Sharma K. Loss of heparan N-sulfotransferase in diabetic liver. Diabetes 2005, 54:1116-1122.
28. Nadanaka S., Kitagawa H. Heparan sulphate biosynthesis and disease. J. Biochem. 2008, 144:7-14.
29. Lindahl U., Kusche-Gullberg M., Kjellen L. Regulated diversity of heparan sulfate. J. Biol. Chem. 1998, 273:24979-24982.
30. Selleck S.B. Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet. 2000, 16:206-212.
31. Esko J.D., Lindahl U. Molecular diversity of heparan sulfate. J. Clin. Invest. 2001, 108:169-173.
32. Ledin J., Staatz W., Li J.P., Gotte M., Selleck S.B., Kjellen L., Spillmann D. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 2004, 279:42732-42741.
33. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
34. Fuster M.M., Wang L., Castagnola J., Sikora L., Reddi K., Lee P.H., Radek K.A., Schuksz M., Bishop J.R., Gallo R.L., Sriramarao P., Esko J.D. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J. Cell Biol. 2007, 177:539-549.
35. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
36. Clowes A.W., Clowes M.M. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ. Res. 1986, 58:839-845.
37. Lindner V., Karnowsky M.J., Clowes A.W., Reidy M.A. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J. Clin. Invest. 1992, 90:2044-2049.
38. Majesky M., Schwartz S., Clowes M., Clowes A. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ. Res. 1987, 61:296-300.
39. Bingley J.A., Hayward I.P., Campbell J.H., Campbell G.R. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Surg. 1998, 28:308-318.
40. Tran P., Tran-Lundmark K., Soininen R., Tryggvason K., Thyberg J., Hedin U. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ. Res. 2004, 94:550-558.
41. Baker A.B., Groothuis A., Jonas M., Ettenson D.S., Shazly T., Zcharia E., Vlodavsky I., Seifert P., Edelman E.R. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ. Res. 2009, 104:380-387.